Valuation: BioNTech SE

Market Cap 21.72B 24.69B 20.54B 18.63B 34.98B 2,370B 35.18B 246B 94.96B 1,209B 92.71B 90.7B 3,887B P/E 2026 *
-15.2x
P/E 2027 * -15.8x
Enterprise Value 10.35B 11.77B 9.79B 8.88B 16.67B 1,129B 16.77B 117B 45.25B 576B 44.18B 43.22B 1,852B EV / Sales 2026 *
5.73x
EV / Sales 2027 * 6.45x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+1.27%
1 week+3.52%
Current month-1.08%
1 month-9.65%
3 months+9.68%
6 months+16.00%
Current year+6.78%
1 week 85
Extreme 85
89.05
1 month 82.95
Extreme 82.95
90.25
Current year 68.65
Extreme 68.65
104
1 year 68.65
Extreme 68.65
104
3 years 68.65
Extreme 68.65
124.5
5 years 68.65
Extreme 68.65
330
10 years 65.89
Extreme 65.89
394.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.27%+3.52% - - 24.75B
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-2.70%+38.19%+86.90% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
+0.19%-2.21%-16.46%+359.36% 25.73B
+1.35%+2.02%+1.92%-2.01% 24.75B
+1.10%+1.86%+25.66%-7.59% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.71%+2.37%+44.38%+161.61% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average +0.09%-0.13%+36.83%+166.13% 30.57B
Weighted average by Cap. +0.12%-1.05%+37.87%+126.51%

Financials

2026 *2027 *
Net sales 1.81B 2.05B 1.71B 1.55B 2.91B 197B 2.93B 20.46B 7.9B 101B 7.71B 7.55B 323B 1.81B 2.06B 1.71B 1.55B 2.92B 198B 2.93B 20.5B 7.92B 101B 7.73B 7.56B 324B
Net income -1.38B -1.57B -1.3B -1.18B -2.22B -150B -2.23B -15.59B -6.02B -76.67B -5.88B -5.75B -246B -1.31B -1.49B -1.24B -1.12B -2.11B -143B -2.12B -14.84B -5.73B -72.98B -5.59B -5.47B -235B
Net Debt -11.37B -12.93B -10.75B -9.75B -18.31B -1,241B -18.42B -129B -49.71B -633B -48.53B -47.48B -2,035B -10.03B -11.4B -9.48B -8.6B -16.15B -1,095B -16.25B -114B -43.85B -559B -42.81B -41.88B -1,795B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
25/09/26 €86.65 +0.35% 0
24/09/26 €86.35 -1.93% 0
23/09/26 €88.05 -1.12% 0
22/09/26 €89.05 +4.83% 6
21/09/26 €84.95 +1.49% 0
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
86.45EUR
Average target price
103.07EUR
Spread / Average Target
+19.23%

Quarterly revenue - Rate of surprise